Irene de Almeida Biasoli

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Ciências da Saúde

Unidade:

Faculdade de Medicina

Departamento:

Departamento de Clínica Médica/FM

ORCID:

https://orcid.org/0000-0001-7265-7691


Formação:

  • Hôpital St Louis

    | Pós-Doutorado | 2007 - 2007

  • Universidade Federal do Rio de Janeiro

    Medicina(clínica médica-hematologia) | Doutorado | 2001 - 2004

  • Universidade Federal do Rio de Janeiro

    Medicina Interna | Mestrado | 1997 - 1999

  • Universidade Federal do Rio de Janeiro

    | Especialização - Residência medica | 1994 - 1997

  • Universidade Federal do Rio de Janeiro

    Medicina | Graduação | 1988 - 1993
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:

(86.36% artigos com DOI)

Titulo DOI Ano
Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry 10.1007/s00277-023-05352-w 2023
Treatment outcomes in classic Hodgkin lymphoma: 5-year update from the Brazilian Hodgkin Lymphoma Registry 10.1002/jha2.804 2023
Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese 10.1016/j.htct.2020.10.966 2021
How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation 10.1016/j.htct.2020.04.002 2020
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma 10.3390/ijerph17051783 2020
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 10.1002/ajh.25674 2019
Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry 10.1002/ijc.31096 2018
Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry 10.1002/hon.2450 2018
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project 10.3324/haematol.2017.186577 2018
New agents in relapsed/refractory Hodgkin's lymphoma 10.1016/j.bjhh.2017.05.003 2017
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 10.3324/haematol.2015.132811 2015
Monoclonal B-cell lymphocytosis 10.1016/j.bjhh.2015.06.003 2015
Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib 10.3109/10428194.2014.974047 2015
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) 10.1093/annonc/mdt562 2014
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry 10.1002/hon.2144 2014
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 10.1016/S2352-3026(14)70008-0 2014
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi 10.1093/annonc/mdt137 2013
Association of social network and social support with health-related quality of life and fatigue in long-term survivors of Hodgkin lymphoma 10.1007/s00520-013-1775-x 2013
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions 10.1002/hon.2029 2013
Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma 10.1093/annonc/mdr157 2012
Psychometric Properties of the Multidimensional Fatigue Inventory in Brazilian Hodgkin's Lymphoma Survivors 10.1016/j.jpainsymman.2011.12.275 2012
Fertility in female survivors of Hodgkin's lymphoma 10.5581/1516-8484.20120014 2012
Follicular lymphoma 10.5581/1516-8484.20120015 2012
CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas 10.1016/j.ajpath.2012.05.015 2012
Validation of the Brazilian Portuguese version of the Medical Outcomes Study-Social Support Survey in Hodgkin's lymphoma survivors 10.1007/s00520-011-1292-8 2011
Nodular, lymphocyte-predominant Hodgkin lymphoma 10.1002/cncr.24819 2010
Changing patterns of AIDS: impact on the indications and diagnostic yield of bone marrow biopsies 10.1590/S1413-86702010000400019 2010
Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma 10.3109/10428190903242628 2009
Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy 10.1093/annonc/mdn391 2008
Evaluation of intra- and interobserver agreement and its clinical significance for scoring bcl-2 immunohistochemical expression in diffuse large B-cell lymphoma 10.1111/j.1440-1827.2008.02276.x 2008
PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma 10.1038/modpathol.3800738 2007
Socioeconomic inequality and short-term outcome in Hodgkin's lymphoma 10.1002/ijc.22417 2007
A Phase II Study of Second-Line Neoadjuvant Chemotherapy With Capecitabine and Radiation Therapy for Anthracycline-Resistant Locally Advanced Breast Cancer 10.1097/01.coc.0000245475.41324.6d 2007
Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile 10.1080/10428190701286470 2007
Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report 10.1007/s11136-006-0009-9 2006
The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma 10.1080/10428190500126034 2005
p53 Expression As a Prognostic Indicator in Hodgkin's Lymphoma 10.1200/JCO.2005.05.159 2005
CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses 10.1111/j.1365-2559.2005.02099.x 2005
Intensified ABVP chemotherapy for the primary treatment of Hodgkin's disease 2002
Application of an adapted international prognostic index for aggressive non Hodgkin's lymphomas: good discrimination and lower survival rates in Rio de janeiro 2001
A double-blind randomized placebo controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients 2000
Predictive value of a positive nasal swab for Aspergillus sp in the diagnosis of invasive aspergillosis in adult neutropenic cancer patients 1999
Delayed G-CSF after autologous bone marrow transplantation 1998
Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients 1998
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
Cohorte Rétrospective de la maladie de Hodgkin à prédominance Lymphocytaire de variété nodulaire: Le suivi à long terme et le risque de transformation en lymphome agressif de 179 patients 2008
A RETROSPECTIVE COHORT OF LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA: A LONG-TERM OUTCOME AND THE RISK OF TRANSFORMATION INTO DIFFUSE LARGE-B CELL LYMPHOMA (APRESENTAÇÃO ORAL) 2008
PROSPECTIVE ANALYSIS OF FACTORS INFLUENCING INCLUSION OF 102 PATIENTS WITH ADVANCED HODGKIN LYMPHOMA IN A RANDOMIZED TRIAL FOR FIRST-LINE CHEMOTHERAPY 2008
The impact of socioeconomic status on the complete remission rate in patients with Hodgkin's disease in Brazil 2006
PKC-BETA II EXPRESSION BY IMMUNOCYTOCHEMISTRY HAS PROGNOSTIC IMPACT IN NODAL DLBCL 2006
The expression of protein kinase C beta II by immunocytochemistry is predicitive of the disease-free survival in diffuse large cell lymphoma. 2006
Bcl-2 translocations and 18q21 gain/amplification in DLBCL with GC and Non-GC phenotype: A TMA and FISH study 2006
Azambuja, D ; STEFANOFF, CG ; PIRES, A. R. C. P. ; BIASOLI, I. ; SPECTOR, N. ; ZALCBERG, I. ; LOPES, V. S. ; MORAIS, J. C. . Immunoblastic lymphomas have a non-germinal center B-cell immunohistochemical profile. In: , 2006, Recife (PE). 2006
The impact of the socioeconomic status on the complete remission rate in patients with Hodgkin's Disease in Brazil - apresentação oral, abstract 0360. , June 2-5, 2005. 2005
The impact of the socioeconomic status on the complete remission rate in patients with Hodgkin's disease. , 2005
Associação dos níveis de Interleucina-10 com o prognóstico de pacientes com doença de Hodgkin". , Rio de Janeiro 2005
Características histopatológicas da medula óssea em 100 pacientes com infecção pelo HIV.ia 2005
CD10 and bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large cell lymphoma with very good or very poor prognoses. 2004
The prognostic value of the expression of bcl-2, p53 and LMP-1 in Hodgkin's disease. 2004
The expression of protein kinase C beta II is predictive of the disease-free survival in diffuse large cell lymphoma., 2004
The prognostic value of the expression of bcl-2, p53 and LMP-1 in Hodgkin's disease. 2004
CD10 and bcl-2 expression combined with the IPI can identify patients with diffuse large cell lymphoma with very low and very high risk. . (apresentação oral). 2004
Avaliação do valor prognóstico da expressão imunoistoquímica de CD10 e bcl-2 em pacientes com linfomas não-Hodgkin difusos de células grandes. . - Prêmio de melhor trabalho de área clínica do congresso. (Apresentação oral) 2003
Impacto do Uso de Hidroxiuréia em pacientes com anemia falciforme no Hospital Universitário Pedro Ernesto. 2001
Síndrome da Pega (SP) após transplante autólogo de células tronco hematopoiéticas (TAMO). 2001
Incidence and factors associated with the engraftment syndrome in autologous stem cell transplantation. 2001
Autologous Peripheral blood progenitors cells transplantation for the treatment of multiple myeloma., 2001
Incidence and factors associated with the engraftment syndrome in autologous stem cell transplantation. , 2000
Transplante autólogo utilizando células progenitoras do sangue periférico. 1999
Quimioterapia em altas doses seguida transplante autólogo com células progenitoras hematopoiéticas no tratamento do mieloma múltiplo. 1999
Fatores associados com a duração da febre em pacientes submetidos a transplante autólogo de células tronco progenitoras. 1999, Foz do Iguaçu. 1999
Ensino de Hematologia: comparação entre um curso baseado em aulas e um curso baseado em problemas. 1999
ABVP chemotherapy as primary therapy for Hodgkin´s disease. 1999
Aplicação do índice prognóstico internacional em pacientes com linfomas não-Hodgkin agressivos. 1999
A double-blind, randomized, placebo-controlled trial of itraconazole capsules for antifungal prophylaxis in neutropenic patients. 1998
Correlation among five different protocols of CD34+ cell enumeration in peripheral blood stem cell harvests, the GM-CFUs and the engraftment period. 1998
Assessing the health behaviors of medical students in Rio de Janeiro, Brazil. 1998
Itraconazol capsules versus placebo in the prophylaxis of fungal infections in neutropenic cancer patients: a double-blind randomized study. , 1998
Fungemia due to Exophiala jeanselmei. Report of 23 cases. 1998
Avaliação do curso clínico de pacientes neutropênicos com candidúria. 1998
Estudo prospectivo duplo-cego itraconazol versus placebo na profilaxia de infecções fúngicas em pacientes neutropênicos com câncer. , 1998
Prevalência de Herpes Zoster em pacientes submetidos a quimioterapia em altas doses seguido de transplante autólogo com células progenitoras hematopoiéticas. 1998
Utilização da associação de ciclofosfamida 1,5 g/m2 e G-CSF 10 mcg/Kg/dia para a mobilização de células progenitoras do sangue periférico. 1998
Quimioterapia em altas doses seguida de resgate com células progenitoras hematopoiéticas no tratamento do mieloma múltiplo. 1998
Quimioterapia em altas doses seguida de resgate com células progenitoras hematopoiéticas no tratamento dos linfomas. 1998
Predictive value of a positive nasal swab for Aspergillus sp. in the diagnosis of systemic aspergillosis in adult neutropenic cancer patients. 1997
Avaliação do curso clínico de pacientes neutropênicos com candidúria. 1997
Valor da colonização nasal por Aspergillus sp no diagnóstico de aspergilose invasiva em pacientes neutropênicos. 1997
Estudo prospectivo duplo-cego itraconazol versus placebo na profilaxia de infecções fúngicas em pacientes neutropênicos com câncer. 1997
Quimioterapia em altas doses seguida de resgate com células progenitoras hematopoiéticas no tratamento dos linfomas. , 1997
Effect of itraconazole prophylaxis on fungal colonization in neutropenic cancer patients. 1996
Efeito do uso profilático de itraconazol na colonização fúngica em pacientes neutropênicos. . 1996
Acompanhamento clínico-hematológico de oito pacientes com Tricoleucemia tratados com análogos das purinas. 1996
Fatores de risco de tiflite em pacientes com neutropenia: estudo caso-controle. 1996
Valor da colonização nasal por Aspergillus sp. no diagnóstico de aspergilose invasiva em pacientes neutropênicos. 1996
Transplante autólogo de células progenitoras da medula óssea ou do sangue periférico. Dois anos de experiência do Hospital Universitário Clementino Fraga Filho da UFRJ. 1996
Síndrome hemolítico-urêmica: uma complicação tardia do transplante autólogo de células progenitoras hematopoiéticas. 1996
Tratamento da Tricoleucemia com análogos das purinas. 1995
Resultados iniciais do tratamento da Doença de Hodgkin em recaída com transplante autólogo de medula óssea. 1995
Publicações:
Minha Rede: